October 23, 2025

Waist Loss Only Part of Semaglutide’s Power

Semaglutide lowered cardiovascular events in patients with overweight or obesity without diabetes, independent of weight loss.

Conexiant

October 22, 2025

Primary Care Workload: 62 Hours Weekly

Electronic records detail physician work hours across multiple primary care clinics.

Conexiant

October 22, 2025

Do GLP-1RAs Differ in Cardiometabolic Protection?

Researchers found that liraglutide and semaglutide offer similar cardiovascular and kidney benefits in type 2 diabetes.

Conexiant

October 20, 2025

FDA Okays First Oral GLP-1 for CV Risk

Novo Nordisk’s once-daily GLP-1 tablet reduced major adverse cardiovascular events in high-risk adults, including those without prior heart attack or stroke.

Conexiant

October 16, 2025

Cardiac Rehab Participation One-Third Lower in Women

Women remain underrepresented in cardiac rehabilitation across all stages of participation.

Conexiant

October 15, 2025

Study Describes Patterns in Reported Drug Interactions

Researchers analyze about 177,000 drug interactions to identify key medication safety trends.

Conexiant

October 10, 2025

Adolescent and Adult VTE After Arthroscopy Compared in Study

Lower venous thromboembolism risk is shown in adolescents than adults after knee arthroscopy, but comorbidities like diabetes and obesity raise risk.

Conexiant

October 06, 2025

Hypertension Drove Atrial Fibrillation Across Study Periods

Incidence rose 44% over three decades, with hypertension as primary driver in all periods

Conexiant

October 03, 2025

Triglyceride-Glucose Index Predicts Coronary Complexity

Researchers evaluate TyG index as a marker to identify severe coronary anatomy in NSTEMI.

Conexiant